Identification | Back Directory | [Name]
7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine | [CAS]
1337531-36-8 | [Synonyms]
CS-868 GSK2606414 GSK2606414, >=98% GSK2606414 (Free base) GSK2606414;GSK-2606414 PERK inhibitor GS2606414 GSK2606414;GSK 2606414;GSK-2606414 GSK2606414,acell-permeableandorallyavailablePERKinhibitor 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)ph 7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine 1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone 7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine USP/EP/BP 1-[5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-2,3-dihydro-1H-indol-1-yl]-2-[3-(trifluoromethyl)phenyl]ethanone Ethanone, 1-[5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2,3-dihydro-1H-indol-1-yl]-2-[3-(trifluoromethyl)phenyl]- GSK2606414/ 7Methyl-5-(1-{[3-(trifluoroMethyl)phenyl]acetyl}-2,3-dihydro1Hindol-5-yl)7Hpyrrolo[2,3d]pyriMidin-4-aMine 7-Methyl-5-[1-[[3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine GSK2606414 | [Molecular Formula]
C24H20F3N5O | [MDL Number]
MFCD25976926 | [MOL File]
1337531-36-8.mol | [Molecular Weight]
451.46 |
Chemical Properties | Back Directory | [Melting point ]
176 - 180°C | [Boiling point ]
720.3±60.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
5.76±0.30(Predicted) | [color ]
Off-White to Pale Yellow |
Hazard Information | Back Directory | [Uses]
GSK 2606414 acts as a potent and selective inhibitor of protein kinase R and similarly endoplasmic reticulum kinase affecting numerous diseases such as cancer. | [storage]
Store at -20°C |
|
|